ABUS: Arbutus Biopharma Corp.
About
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
Current Value
$3.531 Year Return
Current Value
$3.531 Year Return
Key Details
Market Cap
$661.33M
P/E Ratio
-8.19
1Y Stock Return
90.71%
1Y Revenue Growth
-69.69%
Dividend Yield
0.00%
Price to Book
6.2
Strategies that include ABUS
Stock's related to ABUS
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| GIII | 37.98% | $1.28B | +4.84% | 0.00% |
| VIR | 37.33% | $954.40M | -26.51% | 0.00% |
| ALDX | 35.05% | $294.18M | +102.46% | 0.00% |
| PTGX | 34.83% | $2.30B | +122.64% | 0.00% |
| ABCL | 33.91% | $800.44M | -37.56% | 0.00% |
| ONIT | 32.95% | $240.15M | +14.44% | 0.00% |
| ARCT | 32.81% | $489.20M | -21.27% | 0.00% |
| EDIT | 32.75% | $204.72M | -75.49% | 0.00% |
| CERS | 32.73% | $312.00M | -0.59% | 0.00% |
| HOFT | 32.10% | $188.78M | -3.35% | 5.22% |
| CLFD | 31.92% | $398.66M | +4.48% | 0.00% |
| IMVT | 31.74% | $3.70B | -23.48% | 0.00% |
| KIDS | 31.58% | $588.93M | -24.59% | 0.00% |
| MGTX | 31.03% | $467.36M | +9.12% | 0.00% |
| SHEN | 30.70% | $698.36M | -44.66% | 0.79% |
| ORKA | 30.66% | $780.47M | +82.82% | 0.00% |
| EVGO | 30.60% | $625.86M | +97.63% | 0.00% |
| BRSP | 30.17% | $806.64M | -3.86% | 12.20% |
| PLRX | 30.03% | $778.32M | -9.55% | 0.00% |
| NVRI | 29.85% | $552.13M | +20.03% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AIXI | -0.01% | $43.94M | -72.60% | 0.00% |
| REPX | 0.09% | $745.24M | +32.40% | 4.19% |
| NEUE | 0.16% | $40.93M | -34.13% | 0.00% |
| ASPS | 0.17% | $22.36M | -80.26% | 0.00% |
| NGS | -0.18% | $320.33M | +71.20% | 0.00% |
| TTE | 0.21% | $138.45B | -11.95% | 5.50% |
| XP | 0.23% | $9.15B | -27.16% | 0.00% |
| CODX | -0.23% | $34.16M | -25.17% | 0.00% |
| STG | -0.24% | $35.67M | +7.92% | 0.00% |
| PLCE | 0.28% | $194.34M | -20.91% | 0.00% |
| CORZ | -0.34% | $4.60B | +3,201.26% | 0.00% |
| SSSS | 0.36% | - | - | 0.00% |
| CCEC | 0.37% | $1.02B | +28.03% | 3.26% |
| ALL | 0.42% | $52.06B | +45.67% | 1.85% |
| ZH | 0.44% | $333.09M | -40.59% | 0.00% |
| MGY | -0.47% | $5.36B | +26.87% | 1.90% |
| PDD | -0.48% | $163.43B | +0.29% | 0.00% |
| RSG | 0.49% | $66.05B | +31.79% | 1.04% |
| CNQ | 0.52% | $71.04B | +1.89% | 6.81% |
| GL | 0.52% | $9.18B | -8.60% | 0.86% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HUSA | -17.30% | $16.69M | -11.56% | 0.00% |
| NOC | -13.86% | $71.54B | +4.23% | 1.60% |
| MNR | -12.83% | $1.66B | -10.71% | 15.90% |
| VIST | -12.35% | $4.75B | +67.10% | 0.00% |
| CHD | -11.04% | $27.18B | +19.50% | 1.03% |
| MCK | -10.95% | $78.15B | +35.51% | 0.42% |
| LMT | -9.82% | $126.40B | +18.99% | 2.36% |
| PGR | -9.35% | $149.10B | +57.29% | 0.45% |
| PRT | -9.35% | $48.72M | -16.56% | 10.33% |
| CMG | -9.03% | $80.02B | +33.62% | 0.00% |
| HES | -8.68% | $45.06B | +1.32% | 1.24% |
| COR | -8.54% | $47.48B | +21.20% | 0.86% |
| MNSO | -8.38% | $5.45B | -28.63% | 1.56% |
| XOM | -8.38% | $521.39B | +13.56% | 3.22% |
| LNG | -8.32% | $49.37B | +24.99% | 0.82% |
| IMO | -8.29% | $39.72B | +31.84% | 2.23% |
| TPST | -8.04% | $37.75M | -77.59% | 0.00% |
| BEST | -7.76% | $31.65M | +3.88% | 0.00% |
| UUU | -7.74% | $4.97M | -41.89% | 0.00% |
| OXY | -7.44% | $47.39B | -16.87% | 1.66% |
ETF's related to ABUS
News
Finnhub
WARMINSTER - Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B...
Finnhub
The Liver Meeting 2024.The new data are from an additional cohort of participants who received repeat doses of imdusiran, Arbutus' RNAi therapeutic, followed by Barinthus Bio's T-cell stimulating...
Yahoo
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved functional cure Data to be presented in late-breaker poster session at AASLD – The Liver Meeting® on Monday, November 18, 2024 WARMINSTER, Pa., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveragin
Finnhub
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of...
Yahoo
WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will present at and host one-on-one meetings at the following upcoming investor conference: Jefferies London Healthcare Conference: Fireside Chat on November 21, 20
Yahoo
Arbutus Biopharma Corp (ABUS) showcases significant progress in hepatitis B treatment and maintains a robust cash runway into 2026.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.